The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL - Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illes, A., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., Offner, F., Lunin, S., Bosch, F., Davids, M. S., Lamanna, N., Jaeger, U., Ghia, P., Cymbalista, F., Portell, C. A., Skarbnik, A. P., Cashen, A. F., Weaver, D. T., Kelly, V. M., Turnbull, B., Stilgenbauer, S. (American Society of Hematology (ASH), 2018)
6365780